Moreover, the blood miR-4524a-5p expression was negative correlation with Havcr2 expression, providing blood miR-4524a-5p as a new biomarker for the NASH fibrosis patients suitable for anti-TIM3 therapy (Fig. 7I). The gene discussed is HAVCR2; the disease is metabolic dysfunction-associated steatohepatitis.